ID   AMHR2_HUMAN             Reviewed;         573 AA.
AC   Q16671; A0AVE1; B9EGB7; E9PGD2; F8W1D2; Q13762; Q647K2;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 211.
DE   RecName: Full=Anti-Muellerian hormone type-2 receptor;
DE            EC=2.7.11.30;
DE   AltName: Full=Anti-Muellerian hormone type II receptor;
DE            Short=AMH type II receptor;
DE   AltName: Full=MIS type II receptor;
DE            Short=MISRII;
DE            Short=MRII;
DE   Flags: Precursor;
GN   Name=AMHR2; Synonyms=AMHR, MISR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7493017; DOI=10.1038/ng1295-382;
RA   Imbeaud S., Faure E., Lamarre I., Mattei M.-G., di Clemente N., Tizard R.,
RA   Carre-Eusebe D., Belville C., Tragethon L., Tonkin C., Nelson J.,
RA   McAuliffe M., Bidart J.-M., Lababidi A., Josso N., Cate R.L., Picard J.-Y.;
RT   "Insensitivity to anti-Muellerian hormone due to a mutation in the human
RT   anti-Muellerian hormone receptor.";
RL   Nat. Genet. 11:382-388(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7488027; DOI=10.1006/bbrc.1995.2567;
RA   Visser J.A., McLuskey A., van Beers T., Weghuis D.O., van Kessel A.G.,
RA   Grootegoed J.A., Themmen A.P.N.;
RT   "Structure and chromosomal localization of the human anti-Muellerian
RT   hormone type II receptor gene.";
RL   Biochem. Biophys. Res. Commun. 215:1029-1036(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=10589763;
RA   Masiakos P.T., MacLaughlin D.T., Maheswaran S., Teixeira J.,
RA   Fuller A.F. Jr., Shah P.C., Kehas D.J., Kenneally M.K., Dombkowski D.M.,
RA   Ha T.U., Preffer F.I., Donahoe P.K.;
RT   "Human ovarian cancer, cell lines, and primary ascites cells express the
RT   human Muellerian inhibiting substance (MIS) type II receptor, bind, and are
RT   responsive to MIS.";
RL   Clin. Cancer Res. 5:3488-3499(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT HIS-319.
RA   Li H., Ke R., Shen C., Zhou G., Zhong G., Lin L., Yang S.;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH ACVR1.
RX   PubMed=17911401; DOI=10.1677/joe-07-0281;
RA   Renlund N., O'Neill F.H., Zhang L., Sidis Y., Teixeira J.;
RT   "Activin receptor-like kinase-2 inhibits activin signaling by blocking the
RT   binding of activin to its type II receptor.";
RL   J. Endocrinol. 195:95-103(2007).
RN   [9]
RP   VARIANTS PMDS2 CYS-54; VAL-142; GLN-282; GLY-426; 445-GLY--LEU-453 DEL;
RP   ALA-458; HIS-491 AND CYS-504.
RX   PubMed=8872466; DOI=10.1093/hmg/5.9.1269;
RA   Imbeaud S., Belville C., Messika-Zeitoun L., Rey R., di Clemente N.,
RA   Josso N., Picard J.-Y.;
RT   "A 27 base-pair deletion of the anti-Muellerian type II receptor gene is
RT   the most common cause of the persistent Muellerian duct syndrome.";
RL   Hum. Mol. Genet. 5:1269-1277(1996).
RN   [10]
RP   VARIANT PMDS2 GLN-406.
RX   PubMed=11549681; DOI=10.1210/jcem.86.9.7839;
RA   Messika-Zeitoun L., Gouedard L., Belville C., Dutertre M., Lins L.,
RA   Imbeaud S., Hughes I.A., Picard J.-Y., Josso N., di Clemente N.;
RT   "Autosomal recessive segregation of a truncating mutation of anti-
RT   Muellerian type II receptor in a family affected by the persistent
RT   Muellerian duct syndrome contrasts with its dominant negative activity in
RT   vitro.";
RL   J. Clin. Endocrinol. Metab. 86:4390-4397(2001).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two
CC       type II and two type I transmembrane serine/threonine kinases. Type II
CC       receptors phosphorylate and activate type I receptors which
CC       autophosphorylate, then bind and activate SMAD transcriptional
CC       regulators. Receptor for anti-Muellerian hormone.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with type I receptor ACVR1.
CC       {ECO:0000269|PubMed:17911401}.
CC   -!- INTERACTION:
CC       Q16671; P08238: HSP90AB1; NbExp=2; IntAct=EBI-6423788, EBI-352572;
CC       Q16671; P21145: MAL; NbExp=3; IntAct=EBI-6423788, EBI-3932027;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16671-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16671-2; Sequence=VSP_044548;
CC       Name=3;
CC         IsoId=Q16671-3; Sequence=VSP_045281;
CC   -!- DISEASE: Persistent Muellerian duct syndrome 2 (PMDS2) [MIM:261550]: A
CC       form of male pseudohermaphroditism characterized by a failure of
CC       Muellerian duct regression in otherwise normal males.
CC       {ECO:0000269|PubMed:11549681, ECO:0000269|PubMed:8872466}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Anti-Mullerian hormone entry;
CC       URL="https://en.wikipedia.org/wiki/Anti-m%C3%BCllerian_hormone";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X89013; CAA61418.1; -; Genomic_DNA.
DR   EMBL; U29700; AAC50328.1; -; Genomic_DNA.
DR   EMBL; X91156; CAA62593.1; -; Genomic_DNA.
DR   EMBL; X91157; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91158; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91159; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91160; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91161; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91162; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91163; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91164; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91165; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; X91166; CAA62593.1; JOINED; Genomic_DNA.
DR   EMBL; AF172932; AAD48497.1; -; mRNA.
DR   EMBL; AY714878; AAU21221.1; -; mRNA.
DR   EMBL; AK313593; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC068889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC126316; AAI26317.1; -; mRNA.
DR   EMBL; BC136356; AAI36357.1; -; mRNA.
DR   CCDS; CCDS53798.1; -. [Q16671-3]
DR   CCDS; CCDS55829.1; -. [Q16671-2]
DR   CCDS; CCDS8858.1; -. [Q16671-1]
DR   PIR; JC4335; JC4335.
DR   RefSeq; NP_001158162.1; NM_001164690.2. [Q16671-2]
DR   RefSeq; NP_001158163.1; NM_001164691.2. [Q16671-3]
DR   RefSeq; NP_065434.1; NM_020547.3. [Q16671-1]
DR   PDB; 7L0J; X-ray; 2.60 A; B=18-124.
DR   PDBsum; 7L0J; -.
DR   AlphaFoldDB; Q16671; -.
DR   SMR; Q16671; -.
DR   BioGRID; 106766; 59.
DR   IntAct; Q16671; 5.
DR   STRING; 9606.ENSP00000257863; -.
DR   DrugBank; DB00171; ATP.
DR   GlyGen; Q16671; 2 sites.
DR   iPTMnet; Q16671; -.
DR   PhosphoSitePlus; Q16671; -.
DR   BioMuta; AMHR2; -.
DR   DMDM; 9087133; -.
DR   MassIVE; Q16671; -.
DR   PaxDb; Q16671; -.
DR   PeptideAtlas; Q16671; -.
DR   PRIDE; Q16671; -.
DR   ProteomicsDB; 20294; -.
DR   ProteomicsDB; 29591; -.
DR   ProteomicsDB; 61030; -. [Q16671-1]
DR   ABCD; Q16671; 5 sequenced antibodies.
DR   Antibodypedia; 27053; 330 antibodies from 31 providers.
DR   DNASU; 269; -.
DR   Ensembl; ENST00000257863.9; ENSP00000257863.3; ENSG00000135409.11. [Q16671-1]
DR   Ensembl; ENST00000379791.7; ENSP00000369117.3; ENSG00000135409.11. [Q16671-3]
DR   Ensembl; ENST00000550311.5; ENSP00000446661.1; ENSG00000135409.11. [Q16671-2]
DR   GeneID; 269; -.
DR   KEGG; hsa:269; -.
DR   MANE-Select; ENST00000257863.9; ENSP00000257863.3; NM_020547.3; NP_065434.1.
DR   UCSC; uc001scx.2; human. [Q16671-1]
DR   CTD; 269; -.
DR   DisGeNET; 269; -.
DR   GeneCards; AMHR2; -.
DR   HGNC; HGNC:465; AMHR2.
DR   HPA; ENSG00000135409; Tissue enhanced (adrenal gland, ovary).
DR   MalaCards; AMHR2; -.
DR   MIM; 261550; phenotype.
DR   MIM; 600956; gene.
DR   neXtProt; NX_Q16671; -.
DR   OpenTargets; ENSG00000135409; -.
DR   Orphanet; 2856; Persistent Muellerian duct syndrome.
DR   PharmGKB; PA24770; -.
DR   VEuPathDB; HostDB:ENSG00000135409; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   GeneTree; ENSGT00940000160885; -.
DR   HOGENOM; CLU_000288_8_4_1; -.
DR   InParanoid; Q16671; -.
DR   OMA; LTQPPTW; -.
DR   OrthoDB; 390511at2759; -.
DR   PhylomeDB; Q16671; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q16671; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q16671; -.
DR   SIGNOR; Q16671; -.
DR   BioGRID-ORCS; 269; 16 hits in 1105 CRISPR screens.
DR   GenomeRNAi; 269; -.
DR   Pharos; Q16671; Tbio.
DR   PRO; PR:Q16671; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q16671; protein.
DR   Bgee; ENSG00000135409; Expressed in right adrenal gland cortex and 100 other tissues.
DR   ExpressionAtlas; Q16671; baseline and differential.
DR   Genevisible; Q16671; HS.
DR   GO; GO:0048179; C:activin receptor complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0048185; F:activin binding; IBA:GO_Central.
DR   GO; GO:0017002; F:activin receptor activity; IBA:GO_Central.
DR   GO; GO:1990272; F:anti-Mullerian hormone receptor activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042562; F:hormone binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IDA:UniProtKB.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:1990262; P:anti-Mullerian hormone signaling pathway; IDA:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0001880; P:Mullerian duct regression; NAS:UniProtKB.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0007548; P:sex differentiation; ISS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   Gene3D; 2.10.60.10; -; 1.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR015771; Anti-muellerian_hrmn_rcpt_II.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037392; AMHRII; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Disease variant;
KW   Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Pseudohermaphroditism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000255"
FT   CHAIN           18..573
FT                   /note="Anti-Muellerian hormone type-2 receptor"
FT                   /id="PRO_0000024408"
FT   TOPO_DOM        18..149
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..170
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        171..573
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          203..518
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        333
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         209..217
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         230
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   CARBOHYD        66
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        119
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        55..79
FT                   /evidence="ECO:0000250|UniProtKB:P37023"
FT   DISULFID        92..109
FT                   /evidence="ECO:0000250|UniProtKB:P37023"
FT   VAR_SEQ         381..475
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_045281"
FT   VAR_SEQ         430..573
FT                   /note="DSSPPPFQLAYEAELGNTPTSDELWALAVQERRRPYIPSTWRCFATDPDGLR
FT                   ELLEDCWDADPEARLTAECVQQRLAALAHPQESHPFPESCPRGCPPLCPEDCTSIPAPT
FT                   ILPCRPQRSACHFSVQQGPCSRNPQPACTLSPV -> AVHHPSNWPMRQNWAIPLPLMS
FT                   YGPWQCRRGGVPTSHPPGAALPQTLMG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044548"
FT   VARIANT         54
FT                   /note="R -> C (in PMDS2; dbSNP:rs534999427)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015525"
FT   VARIANT         142
FT                   /note="G -> V (in PMDS2)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015526"
FT   VARIANT         282
FT                   /note="H -> Q (in PMDS2; dbSNP:rs539695176)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015527"
FT   VARIANT         319
FT                   /note="R -> H (in dbSNP:rs144236183)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_069048"
FT   VARIANT         406
FT                   /note="R -> Q (in PMDS2; dbSNP:rs137853104)"
FT                   /evidence="ECO:0000269|PubMed:11549681"
FT                   /id="VAR_015528"
FT   VARIANT         426
FT                   /note="D -> G (in PMDS2)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015529"
FT   VARIANT         445..453
FT                   /note="Missing (in PMDS2)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_031057"
FT   VARIANT         458
FT                   /note="V -> A (in PMDS2; dbSNP:rs775889926)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015530"
FT   VARIANT         491
FT                   /note="D -> H (in PMDS2; dbSNP:rs780680518)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015531"
FT   VARIANT         504
FT                   /note="R -> C (in PMDS2; dbSNP:rs772294564)"
FT                   /evidence="ECO:0000269|PubMed:8872466"
FT                   /id="VAR_015532"
FT   CONFLICT        121
FT                   /note="S -> N (in Ref. 4; AAU21221)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        161
FT                   /note="L -> V (in Ref. 2; CAA62593)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        501
FT                   /note="V -> A (in Ref. 4; AAU21221)"
FT                   /evidence="ECO:0000305"
FT   STRAND          23..28
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   HELIX           37..39
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          49..57
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          61..67
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          72..79
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   TURN            85..88
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          95..101
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   STRAND          104..111
FT                   /evidence="ECO:0007829|PDB:7L0J"
FT   TURN            114..117
FT                   /evidence="ECO:0007829|PDB:7L0J"
SQ   SEQUENCE   573 AA;  62750 MW;  1347C10C2942FDBA CRC64;
     MLGSLGLWAL LPTAVEAPPN RRTCVFFEAP GVRGSTKTLG ELLDTGTELP RAIRCLYSRC
     CFGIWNLTQD RAQVEMQGCR DSDEPGCESL HCDPSPRAHP SPGSTLFTCS CGTDFCNANY
     SHLPPPGSPG TPGSQGPQAA PGESIWMALV LLGLFLLLLL LLGSIILALL QRKNYRVRGE
     PVPEPRPDSG RDWSVELQEL PELCFSQVIR EGGHAVVWAG QLQGKLVAIK AFPPRSVAQF
     QAERALYELP GLQHDHIVRF ITASRGGPGR LLSGPLLVLE LHPKGSLCHY LTQYTSDWGS
     SLRMALSLAQ GLAFLHEERW QNGQYKPGIA HRDLSSQNVL IREDGSCAIG DLGLALVLPG
     LTQPPAWTPT QPQGPAAIME AGTQRYMAPE LLDKTLDLQD WGMALRRADI YSLALLLWEI
     LSRCPDLRPD SSPPPFQLAY EAELGNTPTS DELWALAVQE RRRPYIPSTW RCFATDPDGL
     RELLEDCWDA DPEARLTAEC VQQRLAALAH PQESHPFPES CPRGCPPLCP EDCTSIPAPT
     ILPCRPQRSA CHFSVQQGPC SRNPQPACTL SPV
//
